Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in...
Clinical Trial
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor...
Septerna Prices Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a...
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ PlatformREDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE)...
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
WALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase...
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell Multi-year study published...
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis;...
Medicure Announces Positive Settlement of Product Development and Supply Contracts
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
Notable’s AI Platform Now Includes Flow Builder – New Low-Code Interface Unleashes Intelligent Agents to Drive Workforce Productivity and Reduce Administrative Burden
"What surprised me the most is the features and functionality; this is beyond what we're used to. There is power...
Movano Health Plans Response Submission to FDA Next Week as Part of EvieMED Final Review Phase
A successful response to requests for additional information would bring the Company one step closer to introducing this pioneering healthcare...
Caris Life Sciences and ECOG-ACRIN Partner to Interrogate Landmark TAILORx Breast Cancer Trial
The first project under a new multi-year research collaboration, interrogation of the TAILORx breast cancer trial enables discovery for risk...
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndromeBurgeoning pet care market also presents growth opportunities for...
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present...
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for...
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company...
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically...